(NASDAQ: OCUL) TRANSFORMING DRUG DELIVERY LEVERAGING A NOVEL TECHNOLOGY PLATFORM JEFFERIES LONDON HC CONFERENCE DONALD NOTMAN CFO NOVEMBER 21, 2019 FORWARD LOOKING STATEMENTS Any statements in this presentation about future expectations, plans and prospects for the Company, including the commercialization of DEXTENZA®, ReSure® Sealant, or any of the Company's product candidates, including the impact of and restructuring costs and potential future savings associated with the Company's operational restructuri ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2019 Results Earnings Conference Call November 12, 2019 8:00 AM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President and Chief Executive Officer Michael Goldstein - Chief Medical Officer Conference Call Participants Joe Catanzaro - Piper Jaffray Operator Good afternoon, ladies and gentlemen. Thank you for standing by and welcome to the Ocular Therapeutix's Third Quarter Earnings Conference Call. At this time, all participants ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5560161 ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2019 Earnings Conference Call August 7, 2019 4:30 PM ET Company Participants Donald Notman - Chief Financial Officer Antony Mattessich - President and Chief Executive Officer Scott Corning - Senior Vice President, Commercial Michael Goldstein - Chief Medical Officer Conference Call Participants Charles Frantzreb - Piper Jaffray Yi Chen - H.C. Wainwright & Co. Operator Good afternoon, ladies and gentlemen. Thank you for standing by. And welcome to the Ocular Therapeu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5560161 (Sta ...

Start Time: 08:30 January 1, 0000 9:04 AM ET Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q1 2019 Earnings Conference Call May 10, 2019, 08:30 AM ET Company Participants Antony Mattessich - President and CEO Donald Notman - CFO Scott Corning - SVP, Commercial Michael Goldstein - CMO Conference Call Participants Dan Leone - Raymond James Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen. Thank you for standing by. And welcome to the Ocular Therapeutix First Quarter Earnings Conference Call. A ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20-5560161 (St ...

( N A S D AQ: O C U L ) TRANSFORMING DRUG DELIVERY LEVERAGING A NOVEL TECHNOLOGY PLATFORM MICHAEL GOLDSTEIN, M.D., M.B.A. CHIEF MEDICAL OFFICER MARCH 2019 FORWARD LOOKING STATEMENTS Any statements in this presentation about future expectations, plans and prospects for the Company, including the commercialization of DEXTENZA®, ReSure Sealant, or any of the Company's product candidates, development and regulatory status of the Company's product candidates, such as the Company's anticipated commercial launch o ...

Ocular Therapeutix (NASDAQ:OCUL) Q4 2018 Earnings Conference Call March 7, 2019 4:30 PM ET Company Participants Antony Mattessich - President and Chief Executive Officer Donald Notman - Chief Financial Officer Scott Corning - Senior Vice President, Commercial Michael Goldstein - Chief Medical Officer Conference Call Participants Adnan Butt - Guggenheim Securities Dan Leone - Raymond James Operator Good afternoon, ladies and gentlemen, thank you for standing by. And welcome to the Ocular Therapeutix Fourth Q ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) Delaware 20- 5560161 (State o ...